Compare PCG & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCG | GEHC |
|---|---|---|
| Founded | 1995 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3B | 35.8B |
| IPO Year | N/A | 2022 |
| Metric | PCG | GEHC |
|---|---|---|
| Price | $18.20 | $70.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $21.83 | ★ $90.83 |
| AVG Volume (30 Days) | ★ 18.2M | 2.8M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.10% | 0.20% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 4.55 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | $7.12 | $7.06 |
| Revenue Next Year | $3.46 | $4.50 |
| P/E Ratio | ★ $15.15 | $15.47 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $12.97 | $57.65 |
| 52 Week High | $19.16 | $89.77 |
| Indicator | PCG | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 31.78 |
| Support Level | $14.52 | $69.76 |
| Resistance Level | $19.16 | $74.29 |
| Average True Range (ATR) | 0.36 | 2.01 |
| MACD | -0.13 | -0.63 |
| Stochastic Oscillator | 22.45 | 10.41 |
PG&E is a holding company whose main subsidiary is Pacific Gas and Electric, a regulated utility operating in Central and Northern California that serves 5.3 million electricity customers and 4.6 million gas customers in 47 of the state's 58 counties. PG&E operated under bankruptcy court supervision between January 2019 and June 2020. In 2004, PG&E sold its unregulated assets as part of an earlier postbankruptcy reorganization.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).